Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Evaluation of Clinical, Echocardiographic, and Therapeutic Characteristics, and Prognostic Outcomes of Coexisting Heart Failure among Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study

Author(s): Nasr Alrabadi*, Mohammed Al-Nusair, Farah K. El-zubi, Mais Tashtoush, Osama Alzoubi, Sa’ed Khamis, Majd M. Masadeh, Karem H. Alzoubi, Mohammed Al-Hiari and Ayman Hammoudeh*

Volume 22, Issue 1, 2024

Published on: 30 November, 2023

Page: [58 - 66] Pages: 9

DOI: 10.2174/0115701611260211231115094716

Price: $65

Abstract

Background: Atrial fibrillation (AF) is the most commonly encountered cardiac arrhythmia in clinical practice. Heart failure (HF) can occur concurrently with AF.

Aim: We compared different demographic, clinical, and echocardiographic characteristics between patients with AF+HF and patients with AF only. Furthermore, we explored whether concurrent HF independently predicts several outcomes (all-cause mortality, cardiovascular mortality, ischemic stroke/systemic embolism (IS/SE), major bleeding, and clinically relevant non-major bleeding (CRNMB)).

Materials and Methods: Comparisons between the AF+HF and the AF-only group were carried out. Multivariable Cox proportional hazard models were constructed for each outcome to assess whether HF was predictive of any of them while controlling for possible confounding factors.

Results: A total of 2020 patients were included in this study: 481 had AF+HF; 1539 had AF only. AF+HF patients were older, more commonly males, and had a higher prevalence of diabetes mellitus, dyslipidemia, coronary artery disease, and chronic kidney disease (p≤0.05). Furthermore, AF+HF patients more commonly had pulmonary hypertension and low ejection fraction (p≤0.001). Finally, HF was independently predictive of all-cause mortality (adjusted HR 2.17, 95% CI (1.66-2.85) and cardiovascular mortality (adjusted HR 2.37, 95% CI (1.68-3.36).

Conclusion: Coexisting AF+HF was associated with a more labile and higher-risk population among Jordanian patients. Furthermore, coexisting HF independently predicted higher all-cause mortality and cardiovascular mortality. Efforts should be made to efficiently identify such cases early and treat them aggressively.

« Previous Next »
[1]
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics--2015 update: A report from the American Heart Association. Circulation 2015; 131(4): e29-e322.
[http://dx.doi.org/10.1161/CIR.0000000000000152] [PMID: 25520374]
[2]
Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019. J Am Coll Cardiol 2020; 76(25): 2982-3021.
[http://dx.doi.org/10.1016/j.jacc.2020.11.010] [PMID: 33309175]
[3]
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: A report from the american heart association. Circulation 2023; 147(8): e93-e621.
[http://dx.doi.org/10.1161/CIR.0000000000001123] [PMID: 36695182]
[4]
Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk. J Am Coll Cardiol 2022; 80(25): 2361-71.
[http://dx.doi.org/10.1016/j.jacc.2022.11.005] [PMID: 36368511]
[5]
Laslett LJ, Alagona P Jr, Clark BA III, et al. The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues: A report from the American College of Cardiology. J Am Coll Cardiol 2012; 60(25): S1-S49.
[http://dx.doi.org/10.1016/j.jacc.2012.11.002] [PMID: 23257320]
[6]
Biancari F, Teppo K, Jaakkola J, et al. Income and outcomes of patients with incident atrial fibrillation. J Epidemiol Community Health 2022; 76(8): 736-42.
[http://dx.doi.org/10.1136/jech-2022-219190] [PMID: 35705362]
[7]
Essien UR, Kornej J, Johnson AE, Schulson LB, Benjamin EJ, Magnani JW. Social determinants of atrial fibrillation. Nat Rev Cardiol 2021; 18(11): 763-73.
[http://dx.doi.org/10.1038/s41569-021-00561-0] [PMID: 34079095]
[8]
Ohlrogge AH, Brederecke J, Schnabel RB. Global burden of atrial fibrillation and flutter by national income: Results from the global burden of disease 2019 database. J Am Heart Assoc 2023; 12(17): e030438.
[http://dx.doi.org/10.1161/JAHA.123.030438] [PMID: 37646216]
[9]
Tertulien T, Chen Y, Althouse AD, Essien UR, Johnson A, Magnani JW. Association of income and educational attainment in hospitalization events in atrial fibrillation. Am J Prevent Cardiol 2021; 7: 100201.
[http://dx.doi.org/10.1016/j.ajpc.2021.100201] [PMID: 34611640]
[10]
Bhagavathula AS, Shehab A, Ullah A, Rahmani J. The burden of cardiovascular disease risk factors in the middle east: A systematic review and meta-analysis focusing on primary prevention. Curr Vasc Pharmacol 2021; 19(4): 379-89.
[http://dx.doi.org/10.2174/1573406416666200611104143] [PMID: 32525775]
[11]
Zimetbaum P. Atrial fibrillation. Ann Intern Med 2017; 166(5): ITC33-48.
[http://dx.doi.org/10.7326/AITC201703070] [PMID: 28265666]
[12]
Baman JR, Passman RS. Atrial fibrillation. JAMA 2021; 325(21): 2218.
[http://dx.doi.org/10.1001/jama.2020.23700] [PMID: 34061143]
[13]
Falk RH. Atrial fibrillation. N Engl J Med 2001; 344(14): 1067-78.
[http://dx.doi.org/10.1056/NEJM200104053441407] [PMID: 11287978]
[14]
Wadke R. Atrial fibrillation. Dis Mon 2013; 59(3): 67-73.
[http://dx.doi.org/10.1016/j.disamonth.2012.12.002] [PMID: 23410667]
[15]
Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: Clinical implications. J Am Coll Cardiol 2001; 37(2): 371-8.
[http://dx.doi.org/10.1016/S0735-1097(00)01107-4] [PMID: 11216949]
[16]
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285(18): 2370-5.
[http://dx.doi.org/10.1001/jama.285.18.2370] [PMID: 11343485]
[17]
Mkoko P, Bahiru E, Ajijola OA, Bonny A, Chin A. Cardiac arrhythmias in low- and middle-income countries. Cardiovasc Diagn Ther 2020; 10(2): 350-60.
[http://dx.doi.org/10.21037/cdt.2019.09.21] [PMID: 32420117]
[18]
Naser N, Dilic M, Durak A, et al. The impact of risk factors and comorbidities on the incidence of atrial fibrillation. Mater Sociomed 2017; 29(4): 231-6.
[http://dx.doi.org/10.5455/msm.2017.29.231-236] [PMID: 29284990]
[19]
LaMori JC, Mody SH, Gross HJ, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis 2013; 7(2): 53-62.
[http://dx.doi.org/10.1177/1753944712464101] [PMID: 23090783]
[20]
Heijman J, Linz D, Schotten U. Dynamics of atrial fibrillation mechanisms and comorbidities. Annu Rev Physiol 2021; 83(1): 83-106.
[http://dx.doi.org/10.1146/annurev-physiol-031720-085307] [PMID: 33064962]
[21]
Kozieł M, Teutsch C, Halperin JL, et al. Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS One 2021; 16(4): e0249524.
[http://dx.doi.org/10.1371/journal.pone.0249524] [PMID: 33852611]
[22]
Reddy V, Taha W, Kundumadam S, Khan M. Atrial fibrillation and hyperthyroidism: A literature review. Indian Heart J 2017; 69(4): 545-50.
[http://dx.doi.org/10.1016/j.ihj.2017.07.004] [PMID: 28822529]
[23]
McMurray JJV, Pfeffer MA. Heart failure. Lancet 2005; 365(9474): 1877-89.
[http://dx.doi.org/10.1016/S0140-6736(05)66621-4] [PMID: 15924986]
[24]
Baman JR, Ahmad FS. Heart failure. JAMA 2020; 324(10): 1015.
[http://dx.doi.org/10.1001/jama.2020.13310] [PMID: 32749448]
[25]
Chaudhry MA. Heart failure. Curr Hypertens Rev 2019; 15(1): 7.
[http://dx.doi.org/10.2174/157340211501190129144451] [PMID: 30729894]
[26]
Gopinathannair R, Chen LY, Chung MK, et al. Managing atrial fibrillation in patients with heart failure and reduced ejection fraction: A scientific statement from the american heart association. Circ Arrhythm Electrophysiol 2021; 14(7): HAE0000000000000078.
[http://dx.doi.org/10.1161/HAE.0000000000000078] [PMID: 34129347]
[27]
Lee JZ, Cha YM. Atrial fibrillation and heart failure: A contemporary review of current management approaches. Heart Rhythm O2 2021; 2(6 Part B): 762-0.
[http://dx.doi.org/10.1016/j.hroo.2021.11.006]
[28]
Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: Treatment considerations for a dual epidemic. Circulation 2009; 119(18): 2516-25.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.821306] [PMID: 19433768]
[29]
Batul SA, Gopinathannair R. Atrial fibrillation in heart failure: A therapeutic challenge of our times. Korean Circ J 2017; 47(5): 644-62.
[http://dx.doi.org/10.4070/kcj.2017.0040] [PMID: 28955382]
[30]
Bordignon S, Chiara Corti M, Bilato C. Atrial fibrillation associated with heart failure, stroke and mortality. J Atr Fibrillation 2012; 5(1): 467.
[PMID: 28496747]
[31]
Trulock KM, Narayan SM, Piccini JP. Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. J Am Coll Cardiol 2014; 64(7): 710-21.
[http://dx.doi.org/10.1016/j.jacc.2014.06.1169] [PMID: 25125304]
[32]
Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes 2014; 5(4): 444-70.
[http://dx.doi.org/10.4239/wjd.v5.i4.444] [PMID: 25126392]
[33]
Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail 2019; 7(6): 447-56.
[http://dx.doi.org/10.1016/j.jchf.2019.03.005] [PMID: 31146871]
[34]
Sugumar H, Nanayakkara S, Prabhu S, et al. Pathophysiology of atrial fibrillation and heart failure. Cardiol Clin 2019; 37(2): 131-8.
[http://dx.doi.org/10.1016/j.ccl.2019.01.002] [PMID: 30926014]
[35]
Ariyaratnam JP, Lau DH, Sanders P, Kalman JM. Atrial fibrillation and heart failure. Card Electrophysiol Clin 2021; 13(1): 47-62.
[http://dx.doi.org/10.1016/j.ccep.2020.11.004] [PMID: 33516407]
[36]
Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91(6): 2-8.
[http://dx.doi.org/10.1016/S0002-9149(02)03373-8] [PMID: 12670636]
[37]
Kotecha D, Lam CSP, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M. Heart failure with preserved ejection fraction and atrial fibrillation. J Am Coll Cardiol 2016; 68(20): 2217-28.
[http://dx.doi.org/10.1016/j.jacc.2016.08.048] [PMID: 27855811]
[38]
Tsigkas G, Apostolos A, Despotopoulos S, et al. Heart failure and atrial fibrillation: New concepts in pathophysiology, management, and future directions. Heart Fail Rev 2022; 27(4): 1201-10.
[http://dx.doi.org/10.1007/s10741-021-10133-6] [PMID: 34218400]
[39]
Ben Morrison T, Jared Bunch T, Gersh BJ. Pathophysiology of concomitant atrial fibrillation and heart failure: Implications for management. Nat Clin Pract Cardiovasc Med 2009; 6(1): 46-56.
[http://dx.doi.org/10.1038/ncpcardio1414] [PMID: 19047993]
[40]
Kotecha D, Piccini JP. Atrial fibrillation in heart failure: What should we do? Eur Heart J 2015; 36(46): ehv513.
[http://dx.doi.org/10.1093/eurheartj/ehv513] [PMID: 26419625]
[41]
Stefano P, Fabio B, Francesco S, Francesco M. Atrial Fibrillation and the Renin-Angiotensin-Aldosterone System. IntechOpen 2013.
[42]
Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999; 100(1): 87-95.
[http://dx.doi.org/10.1161/01.CIR.100.1.87] [PMID: 10393686]
[43]
Everett TH IV, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007; 4(3): S24-7.
[http://dx.doi.org/10.1016/j.hrthm.2006.12.040] [PMID: 17336879]
[44]
Sridhar A, Nishijima Y, Terentyev D, et al. Chronic heart failure and the substrate for atrial fibrillation. Cardiovasc Res 2009; 84(2): 227-36.
[http://dx.doi.org/10.1093/cvr/cvp216] [PMID: 19567484]
[45]
Burstein B, Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51(8): 802-9.
[http://dx.doi.org/10.1016/j.jacc.2007.09.064] [PMID: 18294563]
[46]
Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87(6): VI102-10.
[PMID: 8500233]
[47]
Verhaert DVM, Brunner-La Rocca HP, van Veldhuisen DJ, Vernooy K. The bidirectional interaction between atrial fibrillation and heart failure: Consequences for the management of both diseases. Europace 2021; 23(23): ii40-5.
[http://dx.doi.org/10.1093/europace/euaa368] [PMID: 33837758]
[48]
Son MK, Park JJ, Lim NK, Kim WH, Choi DJ. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction. Heart 2020; 106(15): 1160-8.
[http://dx.doi.org/10.1136/heartjnl-2019-316219] [PMID: 32341140]
[49]
Țica O, Khamboo W, Kotecha D. Breaking the cycle of heart failure with preserved ejection fraction and atrial fibrillation. Card Fail Rev 2022; 8: e32.
[http://dx.doi.org/10.15420/cfr.2022.03] [PMID: 36644646]
[50]
Dries D, Exner D, Gersh B, Domanski M, Waclawiw M, Stevenson L. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32(3): 695-703.
[http://dx.doi.org/10.1016/S0735-1097(98)00297-6] [PMID: 9741514]
[51]
Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20): 1893-906.
[http://dx.doi.org/10.1056/NEJMoa032292] [PMID: 14610160]
[52]
Hammoudeh A, Khader Y, Tabbalat R, et al. One-year clinical outcome in middle eastern patients with atrial fibrillation: The jordan atrial fibrillation (JoFib) study. Int J Vasc Med 2022; 2022: 1-8.
[http://dx.doi.org/10.1155/2022/4240999] [PMID: 35462945]
[53]
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128(16): e240-327.
[54]
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37(27): 2129-200.
[http://dx.doi.org/10.1093/eurheartj/ehw128] [PMID: 27206819]
[55]
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28(1): 1-39.e14.
[http://dx.doi.org/10.1016/j.echo.2014.10.003] [PMID: 25559473]
[56]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertension 2018; 71(6): e13-e115.
[PMID: 29133356]
[57]
ElSayed NA, Aleppo G, Aroda VR, et al. Classification and diagnosis of diabetes: Standards of care in diabetes-2023. Diabetes Care 2023; 46 (Suppl. 1): S19-40.
[http://dx.doi.org/10.2337/dc23-S002] [PMID: 36507649]
[58]
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158(11): 825-30.
[http://dx.doi.org/10.7326/0003-4819-158-11-201306040-00007] [PMID: 23732715]
[59]
Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa. Circulation 2016; 133(5): 484-92.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.018614] [PMID: 26746177]
[60]
Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107(23): 2920-5.
[http://dx.doi.org/10.1161/01.CIR.0000072767.89944.6E] [PMID: 12771006]
[61]
Miyasaka Y, Barnes ME, Gersh BJ, et al. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: A community-based study over two decades. Eur Heart J 2006; 27(8): 936-41.
[http://dx.doi.org/10.1093/eurheartj/ehi694] [PMID: 16399778]
[62]
Slee A, Saad M, Saksena S. Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction. J Interv Card Electrophysiol 2019; 55(3): 325-31.
[http://dx.doi.org/10.1007/s10840-019-00534-x] [PMID: 30887281]
[63]
Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GYH. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 2016; 203: 660-6.
[http://dx.doi.org/10.1016/j.ijcard.2015.10.220] [PMID: 26580351]
[64]
Cheng M, Lu X, Huang J, Zhang J, Zhang S, Gu D. The prognostic significance of atrial fibrillation in heart failure with a preserved and reduced left ventricular function: Insights from a meta-analysis. Eur J Heart Fail 2014; 16(12): 1317-22.
[http://dx.doi.org/10.1002/ejhf.187] [PMID: 25371247]
[65]
Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 2017; 5(8): 565-74.
[http://dx.doi.org/10.1016/j.jchf.2017.05.001] [PMID: 28711451]
[66]
Melenovsky V, Hwang SJ, Redfield MM, Zakeri R, Lin G, Borlaug BA. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail 2015; 8(2): 295-303.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.114.001667] [PMID: 25593126]
[67]
Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33(12): 1500-10.
[http://dx.doi.org/10.1093/eurheartj/ehr488] [PMID: 22246443]
[68]
Senoo K, Lane D, Lip GYH. Stroke and bleeding risk in atrial fibrillation. Korean Circ J 2014; 44(5): 281-90.
[http://dx.doi.org/10.4070/kcj.2014.44.5.281] [PMID: 25278980]
[69]
Coll-Vinent B, Varona M, Martin A, et al. Association between acute heart failure and major cardiovascular events in atrial fibrillation patients presenting at the emergency department: An EMERG-AF ancillary study. Eur J Emerg Med 2021; 28(3): 210-7.
[http://dx.doi.org/10.1097/MEJ.0000000000000779] [PMID: 33323724]
[70]
Lip GYH, Collet JP, Caterina R, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 2017; 19(11): 1757-8.
[http://dx.doi.org/10.1093/europace/eux240] [PMID: 29096024]
[71]
De Caterina R, Camm AJ. What is ‘valvular’ atrial fibrillation? A reappraisal. Eur Heart J 2014; 35(47): 3328-35.
[http://dx.doi.org/10.1093/eurheartj/ehu352] [PMID: 25265975]
[72]
Yeh YH, Wakili R, Qi XY, et al. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 2008; 1(2): 93-102.
[http://dx.doi.org/10.1161/CIRCEP.107.754788] [PMID: 19808399]
[73]
Ambrosio G, Camm AJ, Bassand JP, et al. Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD-AF. ESC Heart Fail 2021; 8(2): 1139-49.
[http://dx.doi.org/10.1002/ehf2.13156] [PMID: 33434417]
[74]
Mentias A, Briasoulis A, Shantha G, Alvarez P, Vaughan-Sarrazin M. Impact of heart failure type on thromboembolic and bleeding risk in patients with atrial fibrillation on oral anticoagulation. Am J Cardiol 2019; 123(10): 1649-53.
[http://dx.doi.org/10.1016/j.amjcard.2019.02.027] [PMID: 30928033]
[75]
Thomas I. EncisoSilva J, Schlueter M, Greenberg B. Anticoagulation therapy and NOACs in heart failure. Handb Exp Pharmacol 2016; 243: 515-35.
[http://dx.doi.org/10.1007/164_2016_126] [PMID: 28233177]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy